Investor Overview Press Releases August 7, 2024 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update July 16, 2024 Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million June 6, 2024 Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference View all » Events Jun 11, 202411:20 AM EDT Goldman Sachs Global Healthcare Conference May 7, 20245:00 PM EDT Aclaris Therapeutics First Quarter 2024 Conference Call Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results View all » Feature Presentation ITK Portfolio
August 7, 2024 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
July 16, 2024 Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
June 6, 2024 Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results
